Orlando Luana, Bagnato Gianluca, Ioppolo Carmelo, Franzè Maria Stella, Perticone Maria, Versace Antonio Giovanni, Sciacqua Angela, Russo Vincenzo, Cicero Arrigo Francesco Giuseppe, De Gaetano Alberta, Dattilo Giuseppe, Fogacci Federica, Tringali Maria Concetta, Di Micco Pierpaolo, Squadrito Giovanni, Imbalzano Egidio
Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, 88100 Catanzaro, Italy.
Biomedicines. 2023 Mar 17;11(3):939. doi: 10.3390/biomedicines11030939.
During the SARS-CoV-2 pandemic, several biomarkers were shown to be helpful in determining the prognosis of COVID-19 patients. The aim of our study was to evaluate the prognostic value of N-terminal pro-Brain Natriuretic Peptide (NT-pro-BNP) in a cohort of patients with COVID-19.
One-hundred and seven patients admitted to the Covid Hospital of Messina University between June 2022 and January 2023 were enrolled in our study. The demographic, clinical, biochemical, instrumental, and therapeutic parameters were recorded. The primary outcome was in-hospital mortality. A comparison between patients who recovered and were discharged and those who died during the hospitalization was performed. The independent parameters associated with in-hospital death were assessed by multivariable analysis and a stepwise regression logistic model.
A total of 27 events with an in-hospital mortality rate of 25.2% occurred during our study. Those who died during hospitalization were older, with lower GCS and PaO/FiO ratio, elevated D-dimer values, INR, creatinine values and shorter PT (prothrombin time). They had an increased frequency of diagnosis of heart failure ( < 0.0001) and higher NT-pro-BNP values. A multivariate logistic regression analysis showed that higher NT-pro-BNP values and lower PT and PaO/FiO at admission were independent predictors of mortality during hospitalization.
This study shows that NT-pro-BNP levels, PT, and PaO/FiO ratio are independently associated with in-hospital mortality in subjects with COVID-19 pneumonia. Further longitudinal studies are warranted to confirm the results of this study.
在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行期间,有几种生物标志物被证明有助于确定2019冠状病毒病(COVID-19)患者的预后。我们研究的目的是评估N端脑钠肽前体(NT-pro-BNP)在一组COVID-19患者中的预后价值。
2022年6月至2023年1月期间入住墨西拿大学COVID医院的107例患者纳入我们的研究。记录人口统计学、临床、生化、影像学和治疗参数。主要结局是住院死亡率。对康复出院患者与住院期间死亡患者进行比较。通过多变量分析和逐步回归逻辑模型评估与住院死亡相关的独立参数。
在我们的研究期间共发生27例事件,住院死亡率为25.2%。住院期间死亡的患者年龄较大,格拉斯哥昏迷评分(GCS)和动脉血氧分压/吸入氧分数(PaO/FiO)较低,D-二聚体、国际标准化比值(INR)、肌酐值升高,凝血酶原时间(PT)较短。他们心力衰竭的诊断频率增加(<0.0001),NT-pro-BNP值更高。多变量逻辑回归分析显示,入院时较高的NT-pro-BNP值以及较低的PT和PaO/FiO是住院期间死亡的独立预测因素。
本研究表明,NT-pro-BNP水平、PT和PaO/FiO比值与COVID-19肺炎患者的住院死亡率独立相关。需要进一步的纵向研究来证实本研究结果。